Abstract
We measured the CSF tau protein levels in 26 patients with Guillain-Barré syndrome. The levels of the poor outcome group (Hughes grade at 6 months was between II and VI, n = 6) were higher than those of the good outcome group (0 or I, n = 20) (p < 0.0005). The higher levels of CSF tau may reflect axonal degeneration and could predict a poor clinical outcome in Guillain-Barré syndrome.
MeSH terms
-
Adult
-
Aged
-
Antibodies / blood
-
Axons
-
Biomarkers / cerebrospinal fluid
-
Electrodiagnosis
-
Female
-
Glycolipids / immunology
-
Guillain-Barre Syndrome / cerebrospinal fluid*
-
Guillain-Barre Syndrome / complications
-
Guillain-Barre Syndrome / diagnosis
-
Guillain-Barre Syndrome / physiopathology
-
Humans
-
Male
-
Middle Aged
-
Nerve Degeneration / etiology
-
Nerve Degeneration / physiopathology
-
Outcome Assessment, Health Care
-
Prognosis
-
Respiration, Artificial
-
tau Proteins / cerebrospinal fluid*
Substances
-
Antibodies
-
Biomarkers
-
Glycolipids
-
tau Proteins